

Cancer In The News

Alessandro Lagana, PhD, discusses his study determining that the co-occurrence of t(4;14) and 1q gain was effective at identifying newly diagnosed patients with multiple myeloma who were at high risk of relapse. [\[Cancer Network\]](#)

Sundar Jagannath, MBBS, discusses his research finding a lower dose of xpovio may help patients with myeloma get the full benefit of the drug. [\[Cure Today\]](#)

Stephanie Blank, MD, comments on tennis star, Chris Evert's ovarian cancer diagnosis and what to know about prevention. [\[FOX News\]](#)

Scott Friedman, MD, discusses cutting-edge cancer and COVID-19 approaches that could reduce organ scarring. [\[Science\]](#)

Steven Itzkowitz, MD, discusses research that suggests receiving earlier colorectal screenings at age 45 instead of 50. [\[Medpage Today\]](#) [\[M.D. Alert\]](#)

The Icahn School of Medicine enters into a collaboration agreement with Cullinan Oncology to develop novel small molecule immune modulators. [\[The Cancer Letter\]](#)

Mount Sinai Morningside Heights cancer risk stratification company raises \$10.8M. [\[Crain's Health Pulse - Subscription Required\]](#)

Alessandro Lagana, PhD, discusses his study regarding a model developed that may better classify multiple myeloma using genetic sequence data from hundreds of patients. [\[Myeloma Research News\]](#)

Augusto Villanueva Rodriguez, MD, PhD, discusses how an immunotherapy combination significantly improves survival for advanced liver cancer patients. [\[Obr Oncology\]](#)

Raja Flores, MD, and Emanuela Taioli, MD, PhD, discuss their research finding decreased lung cancer mortality rates linked to an earlier diagnosis. [\[ITN Online\]](#)

Thomas Marron, MD, PhD, discusses his study finding that immunotherapy before liver cancer surgery can kill tumors and likely residual cancer cells. [\[FOX 40\]](#) [\[Medical Xpress\]](#) [\[WFMZ\]](#) [\[Market Watch\]](#) [\[Yahoo! Entertainment\]](#) [\[Science Daily\]](#) [\[Healio: Gastroenterology\]](#) [\[Verve Times\]](#)

Joshua Richter, MD, shares background for discussion of his recent publication, "Survival benefit of ixazomib, lenalidomide and dexamethasone [IRD] over lenalidomide and dexamethasone [Rd] in relapsed and refractory multiple myeloma patients in routine clinical practice." [\[Cancer Network\]](#)

Cancer In The News

Thomas Marron, MD, PhD, discusses his study finding that immunotherapy before liver cancer surgery can kill tumors and likely residual cancer cells. [\[Science Daily\]](#) [\[Healio: Gastroenterology\]](#) [\[Verve Times\]](#)

Matthew Galsky, MD, discusses clinical trials that addressed key questions in urothelial cancer. [\[Onc Live\]](#)

Ajai Chari, MD, discusses the takeaways from the PLEIADES trial and its comparability with the CANDOR trial, and how a subcutaneous formulation of a daratumumab combination became a pivotal player in the treatment enhancement for patients with relapsed or refractory multiple myeloma. [\[Onc Live\]](#)

Linda Wu, MD, discusses research finding that underlying liver disease does not affect HCC survival after immune checkpoint inhibition. [\[Healio: Hematology/Oncology\]](#)

Thomas Marron, MD, PhD, discusses his research in a role for neoadjuvant immunotherapy in liver cancer. [\[Medpage Today\]](#) [\[FOX News\]](#)

Matthew Galsky, MD, discusses his research finding results from the CheckMate-274 clinical trial support adjuvant nivolumab as a standard of care for patients with high-risk muscle-invasive urothelial cancer after radical resection. [\[Targeted Oncology\]](#)

Raja Flores, MD, and Emanuela Taioli, MD, PhD, discuss their research finding decreased lung cancer mortality rates linked to an earlier diagnosis. [\[Medscape\]](#)

Samir Parekh, MD, discusses his study highlighting Parkinson's-like toxicity after BCMA-directed CAR T-cell therapy. [\[Healio: Hematology/Oncology\]](#)

Joshua Richter, MD, discusses how the concept of cancer stage does not mean the same thing in multiple myeloma as it does in other cancers, why cytogenetics matter, and new data from trials involving quadruplet therapy. [\[AJMC\]](#)

The Tisch Cancer Institute at Mount Sinai and Samuel Waxman Cancer Research Foundation have launched a research program that will fund collaborations between scientists from the institutions and other cancer research institutions around the world. The program seeks to address the rising rates of cancer due to aging. [\[Crain's Health Pulse - Subscription Required\]](#) [\[Mirage News\]](#)

Thomas Marron, MD, PhD, discusses his research surrounding neoadjuvant cemiplimab for resectable hepatocellular carcinoma, a single-arm, open-label, phase 2 trial. [\[OncologyTube\]](#)

Augusto Villanueva, MD, PhD, discusses his study on immunotherapy in early-stage hepatocellular carcinoma. [\[OncologyTube\]](#)

Cancer In The News

Ashley Tsang, MD, discusses different types of breast cancer and treatments during Cancer Prevention Month. [[Yonker's Times](#)]

The Dubin Breast Center of The Tisch Cancer Institute raised over \$2.5M during its 11th annual online benefit at the end of 2021, utilizing the funds for research and clinical trials, cold cap technology to prevent hair loss during chemotherapy and personalized wellness services for patients. [[Crain's Health Pulse - Subscription Required](#)]

Raja Flores, MD, discusses how banning asbestos is a giant leap forward for Biden's Cancer Moonshot. [[The Hill](#)]

Jose Javier Bravo-Cordero, PhD, discusses his research on finding how collagen could aid in cancer metastasis by keeping dormant tumor cells asleep. [[The Hamden Journal](#)]

The Tisch Cancer Institute and the Samuel Waxman Cancer Research Foundation are launching a unique research program that will fund collaborations between TCI physician-scientists and colleagues from other established cancer research institutions to address the rising rates of cancer due to aging around the world. [[OncLive](#)]